Seeking Alpha

AbbVie's SKYRIZI® (risankizumab) Versus STELARA® (ustekinumab) Head-to-Head Study in Crohn's Disease Meets All Primary and Secondary Endpoints

* The first primary endpoint was clinical remission (per CDAI) at week 24, and the second primary endpoint was endoscopic remission (per SES-CD) at week 48. Non-inferiority was met for the first ...
Healio

Skyrizi outperforms Stelara in endoscopic remission at week 48 in Crohn’s disease

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Risankizumab was noninferior to ustekinumab in clinical ...
Monthly Prescribing Reference

Risankizumab vs Ustekinumab in Patients With Crohn Disease: Trial Results

Topline results were announced from a head-to-head study comparing risankizumab (Skyrizi ®) to ustekinumab (Stelara ®) in patients with moderately to severely active Crohn disease who have failed at ...
Seeking Alpha

AbbVie's SKYRIZI® (risankizumab) Met All Primary and Secondary Endpoints Versus Stelara® (ustekinumab) in Head-to-Head Study in Crohn's Disease

NORTH CHICAGO, Ill., Sept. 12, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced top-line results from the Phase 3 SEQUENCE clinical trial evaluating risankizumab (SKYRIZI ®, 600 mg intravenous ...